- Home
- TBRG vs PSNL Comparison
TBRG vs PSNL Comparison
Compare TBRG & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- PSNL
- Stock Information
- Founded
- TBRG 1979
- PSNL 2011
- Country
- TBRG United States
- PSNL United States
- Employees
- TBRG N/A
- PSNL N/A
- Industry
- TBRG
- PSNL Medical Specialities
- Sector
- TBRG
- PSNL Health Care
- Exchange
- TBRG NYSE
- PSNL Nasdaq
- Market Cap
- TBRG 420.4M
- PSNL 460.7M
- IPO Year
- TBRG N/A
- PSNL 2019
- Fundamental
- Price
- TBRG $28.26
- PSNL $4.72
- Analyst Decision
- TBRG Buy
- PSNL Strong Buy
- Analyst Count
- TBRG 3
- PSNL 4
- Target Price
- TBRG $14.67
- PSNL $7.81
- AVG Volume (30 Days)
- TBRG 151.1K
- PSNL 1.1M
- Earning Date
- TBRG 03-03-2025
- PSNL 02-27-2025
- Dividend Yield
- TBRG N/A
- PSNL N/A
- EPS Growth
- TBRG N/A
- PSNL N/A
- EPS
- TBRG N/A
- PSNL N/A
- Revenue
- TBRG $337,674,000.00
- PSNL $87,489,000.00
- Revenue This Year
- TBRG $1.02
- PSNL $16.00
- Revenue Next Year
- TBRG $5.89
- PSNL $1.29
- P/E Ratio
- TBRG N/A
- PSNL N/A
- Revenue Growth
- TBRG 0.26
- PSNL 24.05
- 52 Week Low
- TBRG $7.55
- PSNL $1.14
- 52 Week High
- TBRG $29.27
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- TBRG 74.04
- PSNL 43.46
- Support Level
- TBRG $27.85
- PSNL $4.47
- Resistance Level
- TBRG $29.27
- PSNL $6.43
- Average True Range (ATR)
- TBRG 1.05
- PSNL 0.51
- MACD
- TBRG 0.05
- PSNL 0.00
- Stochastic Oscillator
- TBRG 80.80
- PSNL 12.50
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.